Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Venous Thromboembolism (VTE): later-stage trial registry
1 of 4 indexed Venous Thromboembolism (VTE) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Venous Thromboembolism (VTE): 4 US clinical trials tracked, 1 recruiting.
Venous Thromboembolism (VTE) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Portola Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition venous-thromboembolism-vte
OPEN 1 | RECR 25% | LATE 3 | EARLY 0 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Venous Thromboembolism (VTE) lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Venous Thromboembolism (VTE) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Venous Thromboembolism (VTE) is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Regeneron Pharmaceuticals
NCT07015905
A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot
Bristol-Myers Squibb
NCT03521908
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
Portola Pharmaceuticals
NCT01583218
Cancer Venous Thromboembolism (VTE)
Daiichi Sankyo
NCT02073682
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Venous Thromboembolism (VTE) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Venous Thromboembolism (VTE) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Venous Thromboembolism (VTE) page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Venous Thromboembolism (VTE) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Portola Pharmaceuticals sponsors the most Venous Thromboembolism (VTE) trials on record, review their full trial history before evaluating a specific study. See Portola Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Venous Thromboembolism (VTE) condition card totals 4 registered trials; most-linked intervention Enoxaparin; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.